“…Cytomegalovirus (CMV) is a virus that is associated with serious conditions such as mononucleosis and hepatitis in immunocompromised patients. Valganciclovir (VGC) is a first-line antiviral drug that is used for the treatment of CMV infections. , After oral administration, it undergoes hydrolysis in the intestine by hepatic esterase, which is a hydrolase enzyme, and is rapidly converted into ganciclovir (i.e., VGC is a prodrug of ganciclovir). , This drug was approved by the Food and Drug Administration in the year 2001 for the treatment of CMV infections. The major side effect of VGC is a decrease in the function of bone marrow, which leads to a drop in the level of blood cells (e.g., RBCs, WBCs, and platelets) and a decrease in the body’s immune response.…”